Overzicht belangen werkgroepleden
Uit Richtlijnen HIV
(Verschil tussen bewerkingen)
| Regel 191: | Regel 191: | ||
| Viiv Healthcare | | Viiv Healthcare | ||
| align="center" | x | | align="center" | x | ||
| - | | | + | | align="center" | x |
| align="center" | x | | align="center" | x | ||
| | | | ||
| Regel 212: | Regel 212: | ||
| Roche | | Roche | ||
| | | | ||
| - | | | + | | align="center" | x |
| align="center" | x | | align="center" | x | ||
| | | | ||
| Regel 224: | Regel 224: | ||
|- | |- | ||
| | | | ||
| + | | Schering-Plough | ||
| | | | ||
| - | | | + | | align="center" | x |
| - | | | + | |
| | | | ||
| | | | ||
Versie op 4 jun 2010 12:06
| Naam | Firma |
Consultatie/ advisering |
Wetenschappelijk onderzoek |
Congres/ andere reis | Cursus |
| Kees Brinkman | Viiv | x | x | x | |
| BMS | x | ||||
| MSD | x | x | |||
| Gilead | x | x | x | ||
| Roche | x | ||||
| Abbott | x | x | |||
| Jansen-Tibotec | x | x | x | ||
| Mariska Tuut | Geen | ||||
| Suzanne Geerlings | MSD | x | x | ||
| GSK | x | ||||
| BMS | x | x | |||
| Gilead | x | x | |||
| Abbott | x | x | |||
| Jansen Cilag (Tibotec) | x | ||||
| Pfizer | x | ||||
| Jet Gisolf | Roche | x | |||
| Merck | x | ||||
| Gilead | x | ||||
| Shering Plough | x | ||||
| Abbott | x | ||||
| Gerrit Schreij | Viiv Healthcare | x | x | x | |
| Gilead | x | ||||
| Tibotec | x | ||||
| Roche | x | x | |||
| MSD | x | ||||
| Schering-Plough | x | ||||
Door de werkgroepleden opgegeven relaties in de periode 2005-2010